Company intelligence / Profile preview

Alume Biosciences

San Diego, California, United Statesalumebiosciences.com ↗

Ownership: Private
Employees: ~18
Development stage: Phase 3

Overview

Alume Biosciences is conducting Phase 3 clinical trials of their lead product ALM-488, a fluorescent peptide-dye conjugate designed to highlight nerves in real time during surgery. They successfully completed Phase 1/2 studies in patients undergoing Head and Neck Surgery in 2021. The Phase 3 studies are being conducted at multiple academic medical centers throughout the US and were projected to be completed in 2023, with FDA submission targeted for 2025[2][7].

Therapeutic areas: Other
Modalities: Peptide-dye conjugates
Industry: Biotech

Drug pipeline

2 assets

bevonescein

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Alume Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alume Biosciences.

Explore the full profile